このエントリーをはてなブックマークに追加
ID 67864
FullText URL
fulltext.pdf 1.13 MB
Author
Inukai-Motokura, Yumi Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ninomiya, Kiichiro Department of Allergy and Respiratory Medicine, Okayama University Hospital Kaken ID
Baba, Takahiro Department of Allergy and Respiratory Medicine, Okayama University Hospital
Omori, Hiroki Department of Allergy and Respiratory Medicine, Okayama University Hospital
Takeguchi, Tetsuya Department of Allergy and Respiratory Medicine, Okayama University Hospital
Uno, Mari Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ayada, Yoshiyuki Department of Pathology, Okayama University Hospital
Tanaka, Takehiro Department of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University ORCID Kaken ID publons
Maeda, Yoshinobu Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID researchmap
Ohashi, Kadoaki Department of Allergy and Respiratory Medicine, Okayama University Hospital ORCID Kaken ID researchmap
Abstract
Pulmonary sclerosing pneumocytoma (PSP) is a rare form of lung cancer that occasionally presents with lymph node and extrapulmonary metastases, and multiple lesions. The treatment of metastatic PSP remains undefined. This study reports the case of a 48-year-old female patient diagnosed with PSP following surgical intervention for a solitary nodule in the left lower lobe. Four years later, recurrence occurred in the left hilar and mediastinal lymph nodes, necessitating an additional resection. Concurrently, sacral metastases developed and required palliative radiotherapy. Genetic analysis identified an AKT1 E17K mutation, characteristic of PSP, and absence of programmed cell death ligand 1 (PD-L1) expression in the tumor. Two years post-recurrence, the tumor recurred in the left mammary gland and mediastinal lymph nodes. Combination immunotherapy with ipilimumab and nivolumab yielded a significantly positive response in this metastatic PSP case. This is the first reported case of successful treatment of multiple distant metastatic PSP with ipilimumab and nivolumab, following the failure of various local treatments. Further case series are warranted to validate the efficacy of immunotherapy in metastatic PSP.
Keywords
Pulmonary sclerosing pneumocytoma
Ipilimumab
Nivolumab
Programmed cell death ligand 1
Case report
Published Date
2024-11-29
Publication Title
International Cancer Conference Journal
Volume
volume14
Issue
issue1
Publisher
Springer Science and Business Media LLC
Start Page
60
End Page
63
ISSN
2192-3183
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© The Author(s) 2024
File Version
publisher
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.1007/s13691-024-00737-8
License
http://creativecommons.org/licenses/by/4.0/
Citation
Inukai-Motokura, Y., Ninomiya, K., Baba, T. et al. Successful immunotherapy with ipilimumab and nivolumab in a patient with pulmonary sclerosing pneumocytoma. Int Canc Conf J 14, 60–63 (2025). https://doi.org/10.1007/s13691-024-00737-8
Funder Name
Okayama University